Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jun, 2016 | Pages:
49 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Arbutus Biopharma Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct's, 'Arbutus Biopharma Corporation - Product Pipeline Review - 2016', provides an overview of the Arbutus Biopharma Corporation's pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Arbutus Biopharma Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the pipeline therapeutic landscape of Arbutus Biopharma Corporation - The report provides overview of Arbutus Biopharma Corporation including its business description, key facts, and locations and subsidiaries - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report assesses Arbutus Biopharma Corporation's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report features Arbutus Biopharma Corporation's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects Reasons To Buy - Evaluate Arbutus Biopharma Corporation's strategic position with total access to detailed information on its product pipeline - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Arbutus Biopharma Corporation - Identify potential new clients or partners in the target demographic - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Arbutus Biopharma Corporation's pipeline depth and focus of pipeline therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Arbutus Biopharma Corporation Snapshot 6 Arbutus Biopharma Corporation Overview 6 Key Information 6 Key Facts 6 Arbutus Biopharma Corporation - Research and Development Overview 7 Key Therapeutic Areas 7 Arbutus Biopharma Corporation - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Pipeline Products - Partnered Products 11 Partnered Products/Combination Treatment Modalities 12 Pipeline Products - Out-Licensed Products 13 Out-Licensed Products/Combination Treatment Modalities 14 Arbutus Biopharma Corporation - Pipeline Products Glance 15 Arbutus Biopharma Corporation - Clinical Stage Pipeline Products 15 Phase II Products/Combination Treatment Modalities 15 Arbutus Biopharma Corporation - Early Stage Pipeline Products 16 Preclinical Products/Combination Treatment Modalities 16 Discovery Products/Combination Treatment Modalities 17 Arbutus Biopharma Corporation - Drug Profiles 18 ARB-1467 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 AB-423 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 ARB-1740 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 ARB-199 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 ARB-596 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 CCC-0346 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CCC-0975 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CYT-003QbG10 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecules to Inhibit HBsAg for Hepatitis B 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 DVR-23 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecules for Hepatitis B Infection 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecules to Agonize Sting Receptor for Hepatitis B 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 Small Molecules to Inhibit Ribonuclease H for Hepatitis B 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Arbutus Biopharma Corporation - Pipeline Analysis 35 Arbutus Biopharma Corporation - Pipeline Products by Target 35 Arbutus Biopharma Corporation - Pipeline Products by Route of Administration 36 Arbutus Biopharma Corporation - Pipeline Products by Molecule Type 37 Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action 38 Arbutus Biopharma Corporation - Recent Pipeline Updates 39 Arbutus Biopharma Corporation - Dormant Projects 44 Arbutus Biopharma Corporation - Discontinued Pipeline Products 45 Discontinued Pipeline Product Profiles 45 INX-3280 45 NVP-018 45 RNAi Oligonucleotide to Inhibit CSN5 for Hepatocellular Carcinoma 45 RNAi Oligonucleotide to Inhibit WEE1 for Hepatocellular Carcinoma 45 Small Molecules for Dengue 46 TKM-100802 46 TKM-130803 46 TKM-ALDH2 46 TKM-GSD 46 TKM-HTG 46 TKM-Marburg 46 TKM-PLK1 46 TKMApoC-3 46 Arbutus Biopharma Corporation - Locations And Subsidiaries 47 Head Office 47 Other Locations & Subsidiaries 47 Appendix 48 Methodology 48 Coverage 48 Secondary Research 48 Primary Research 48 Expert Panel Validation 48 Contact Us 48 Disclaimer 49
List of Tables
Arbutus Biopharma Corporation, Key Information 6 Arbutus Biopharma Corporation, Key Facts 6 Arbutus Biopharma Corporation - Pipeline by Indication, 2016 8 Arbutus Biopharma Corporation - Pipeline by Stage of Development, 2016 9 Arbutus Biopharma Corporation - Monotherapy Products in Pipeline, 2016 10 Arbutus Biopharma Corporation - Partnered Products in Pipeline, 2016 11 Arbutus Biopharma Corporation - Partnered Products/ Combination Treatment Modalities, 2016 12 Arbutus Biopharma Corporation - Out-Licensed Products in Pipeline, 2016 13 Arbutus Biopharma Corporation - Out-Licensed Products/ Combination Treatment Modalities, 2016 14 Arbutus Biopharma Corporation - Phase II, 2016 15 Arbutus Biopharma Corporation - Preclinical, 2016 16 Arbutus Biopharma Corporation - Discovery, 2016 17 Arbutus Biopharma Corporation - Pipeline by Target, 2016 35 Arbutus Biopharma Corporation - Pipeline by Route of Administration, 2016 36 Arbutus Biopharma Corporation - Pipeline by Molecule Type, 2016 37 Arbutus Biopharma Corporation - Pipeline Products by Mechanism of Action, 2016 38 Arbutus Biopharma Corporation - Recent Pipeline Updates, 2016 39 Arbutus Biopharma Corporation - Dormant Developmental Projects,2016 44 Arbutus Biopharma Corporation - Discontinued Pipeline Products, 2016 45 Arbutus Biopharma Corporation, Subsidiaries 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
